Abstract: The invention concerns monoclonal antibodies against a complex of human ACT and a serine protease, preferably against a ACT-PSA, which have essentially no cross-reactivity with free, non-complexed human ACT and with free, non-complexed PSA, as well as diagnostic test methods for detecting serine protease-ACT complexes, in particular PSA-ACT, using these monoclonal antibodies.

Abstract: The invention concerns monoclonal antibodies against a complex of human ACT and a serine protease, preferably against a ACT-PSA, which have essentially no cross-reactivity with free, non-complexed human ACT and with free, non-complexed PSA, as well as diagnostic test methods for detecting serine protease-ACT complexes, in particular PSA-ACT, using these monoclonal antibodies.

Abstract: The present invention concerns an antibody against a hepatitis G virus antigen as well as a fragment of this antibody. The invention additionally concerns hybridoma cell lines as well as a conjugate that contains this antibody or the antibody fragment coupled to a biological molecule. Finally the present invention concerns the use of the antibody for the diagnostic detection of hepatitis G virus.

Abstract: A method for determining collagen degradation products in a body fluid sample using a non-competitive or competitive immunoassay is disclosed, the method comprising incubating the body fluid sample with an amount of antibody which specifically reacts with the amino acid sequence of SEQ ID NO. 2 of collagen l or a fragment thereof, and determining the collagen degradation products bound to the amount of the antibody. A kit for such a method is also disclosed.

Abstract: The invention concerns monoclonal antibodies which bind to the CK-MB isoenzyme but not to the B or M subunit of CK-MB or to the CK-MM and CK-BB isoenzmyes, as well as a method for the diagnostic detection of CK-MB in a homogeneous diagnostic test using these antibodies.

Abstract: The invention provides for monoclonal antibodies which specifically bind to type I phospholipase A.sub.2 for use as a diagnostic agent and as an anti-inflammatory therapeutic agent, which is particularly suitable for application in acute pancreatitis. The invention further provides for pharmaceutical compositions including the antibodies of the invention. The invention also provides for a method for treating subjects suffering from inflammatory symptoms and for detecting the activity of type I phospholipase A.sub.2 in a sample.

Abstract: Disclosed are antibodies which specifically bind the amino acid sequence of SEQ ID NO. 1 of collagen I. A hybridoma cell line which produces the antibodies is also disclosed.

Abstract: Immunogens of formula I are provided for obtaining HbA.sub.1c -specific antibodies ##STR1## M is 1 to 40, T is a carrier protein and A is a 10-20 atoms spacer and is ##STR2## where X is S or --NH--, n is 1 to 4 and B is a succinimide containing organic radical. The antibodies obtained bind glycosylated hemoglobin to determine HbA.sub.1c in body fluids.

Abstract: The present invention provides immunogens for obtaining HbA.sub.1c -specific antibodies, which immunogens have the general formula: ##STR1## wherein M is 1 to 40, T is a carrier protein and A is a spacer which has a chain length of 10 to 20 atoms and has the general formula: ##STR2## wherein X is a sulphur atom or au --NH-- group, n is 1 to 4 and B is an organic radical which contains a succinimide group. The present invention also provides a process for obtaining antibodies which specifically bind glycosylated haemoglobin, wherein an immunogen of general formula (I) is injected into an organism capable of antibody formation and the antibodies are then obtained in known manner. These antibodies can be used for determining HbA.sub.1c in body fluids.

Abstract: A method for making an monoclonal antibody specific for vitamin B12 by immunizing mice with vitamin B12-b-acid and isolating hybridomas that produce monoclonal antibodies which have an affinity constant for B12 greater than 5.times.10.sup.9 l/mol is disclosed.

Abstract: For the determination of vitamin B12 a sample solution is incubated with at least two receptors R.sub.1 and R.sub.2 of which R.sub.1 mediates the binding to the solid phase and R.sub.2 is labelled, whereby a receptor is used as one of the receptors R.sub.1 or R.sub.2 which contains a monoclonal antibody capable of specific binding to B12 that has an affinity constant of at least 5.times.10.sup.9 l/mol and a receptor is used as the other receptor R.sub.1 or R.sub.2 which contains B12 or an analogue thereof, the two phases are separated and the label is measured in one of the two phases.

Abstract: The present invention provides an immunological process for the determination of the luteinizing hormone (LH), wherein at least one monoclonal antibody is used which is directed against LH and cross-reacts with other glycoprotein hormones to an extent of less than 3%.The present invention also provides a reagent for the determination of the luteinizing hormone, wherein it contains at least one monoclonal antibody which is directed against LH and cross-reacts with other glycoprotein hormones to an extent of less than 3%.Furthermore, the present invention provides a monoclonal antibody against the luteinizing hormone and a process and a hybridoma cell line for producing it.

Abstract: In body fluids containing saliva alpha amylase and pancreatic alpha amylase, pancreatic alpha amylase is determined with a monoclonal antibody which specifically binds but does not inhibit saliva alpha amylase and which has a cross-reactivity of 5% or less toward pancreatic alpha amylase. The monoclonal antibody binds salvia alpha amylase to form a complex which is separated to permit determining pancreatic alpha amylase with an amylase detection system. The complex may be separated by precipitating with a precipitating agent such as an anti-antibody or protein A, or by immobilizing the monoclonal antibody on a solid carrier.

Abstract: The present invention provides an immunological process for the determination of the follicle-stimulating hormone (FSH), wherein there is used at least one monoclonal antibody which is directed specifically against FSH and cross-reacts with other glycoprotein hormones to an extent of less than 3%.The present invention also provides a reagent for the determination of the follicle-stimulating hormone, wherein it contains at least one monoclonal antibody which is directed against FSH and cross-reacts with other glycoprotein hormones to an extent of less than 3%.Furthermore, the present invention provides a monoclonal antibody against the follicle-stimulating hormone and a process and a hybridoma cell line for producing it.